COXANTO

Growth

oxaprozin

NDAORALCAPSULE
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
30/100

Mechanism of Action

Cyclooxygenase Inhibitors

Pharmacologic Class:

Nonsteroidal Anti-inflammatory Drug

Indications (2)

rheumatoid arthritisFor relief of the signs and symptoms of osteoarthritis
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers